Rethinking Lipoprotein(a) Trial Design: The Case for Phenotype-Guided Enrichment

Lipoprotein(a) [Lp(a)] is an unusual cardiovascular risk factor.Its plasma concentration is largely genetically determined, is essentially fixed from early childhood, and is barely influenced by lifestyle or the more commonly used lipid-lowering drugs.Epidemiological, genetic and Mendelian randomisation studies converge on a causal role in both atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis [1-3].Around one in five people of European ancestry carry levels above 105 nmol/L, which per se are considered a cardiovascular risk-enhancing factor, and guidelines on both sides of the Atlantic now recommend measuring Lp(a) at least once in every adult [1,4,5].Yet, until now, there has been no targeted treatment to offer those found to be at risk.

Authors

Publication Details

Journal
European Journal of Preventive Cardiology
Published
2026-11-18
DOI
https://doi.org/10.1093/eurjpc/zwag593
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rethinking Lipoprotein(a) Trial Design: The Case for Phenotype-Guided Enrichment

Carlos Aguíar
4 links
European Journal of Preventive Cardiology
Lipoproteins and Cardiovascular Health
article

Rethinking Lipoprotein(a) Trial Design: The Case for Phenotype-Guided Enrichment

Carlos Aguíar
article en

Abstract

Lipoprotein(a) [Lp(a)] is an unusual cardiovascular risk factor.Its plasma concentration is largely genetically determined, is essentially fixed from early childhood, and is barely influenced by lifestyle or the more commonly used lipid-lowering drugs.Epidemiological, genetic and Mendelian randomisation studies converge on a causal role in both atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis [1-3].Around one in five people of European ancestry carry levels above 105 nmol/L, which per se are considered a cardiovascular risk-enhancing factor, and guidelines on both sides of the Atlantic now recommend measuring Lp(a) at least once in every adult [1,4,5].Yet, until now, there has been no targeted treatment to offer those found to be at risk.

European Journal of Preventive Cardiology
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon